Geptanolimab
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1) . Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1].
Product Specifications
CAS Number
2348469-43-0
Product Name Alternative
Genolimzumab; APL-501; CBT-501; GB-226
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/geptanolimab.html
Purity
97.72
Solubility
10 mM in DMSO
Smiles
[Geptanolimab]
Molecular Weight
(144.14 kDa)
References & Citations
[1]Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7_suppl) :108-108.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
